[MO2] Mini-Oral Session 2　Hepatobiliary / Pancreatic Cancer 1（Pancreatic Cancer 1）
【E】

[MO2-2] HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma

^○Masayoshi Dazai¹, Kazuaki Harada², Takahiro Yamamura³, Osamu Muto⁴, Michio Nakamura⁵, Susumu Sogabe⁶, Kentaro Sawada⁷, Masataka Yagisawa⁸, Tetsuhito Muranaka⁹, Shintaro Nakano¹⁰, Miki Tateyama¹¹, Ken Ito³, Rika Saito³, Yoshimitsu Kobayashi⁶, Sosuke Kato¹, Takuto Miyagishima¹², Yasuyuki Kawamoto³, Satoshi Yuki², Yuh Sakata¹³, Yoshito Komatsu³ (1.Department of Gastroenterology, Sapporo Medical Center NTT EC, Sapporo, Japan, 2.Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, 3.Division of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, 4.Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan, 5.Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan, 6.Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan, 7.Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, 8.Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Kitami, Japan, 9.Department of Internal Medicine, Wakkanai City Hospital, Wakkanai, Japan, 10.Department of Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa, Japan, 11.Department of Gastroenterology, Tomakomai Nissho Hospital, Tomakomai, Japan, 12.Department of Internal Medicine, Kushiro Rosai Hospital, Kushiro, Japan, 13.Department of Medical Oncology, Misawa City Hospital, Misawa, Japan)